SCHEMBL6409451

SCHEMBL6409451

COc1ccc(NS(=O)(=O)CN(CCCc2ccccc2)C(=O)N(CCC(C)C)C(=O)c2cccc(NC(=O)O)c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.39
LPAR1 Q92633 3/20 0.39
MAPT P10636 3/20 0.38
LMNA P02545 2/20 0.38
ALDH1A1 P00352 2/20 0.38
CASR P41180 2/20 0.38
LIMK2 P53671 1/20 0.38
HPGD P15428 1/20 0.37
NR1H4 Q96RI1 1/20 0.37
MEN1 O00255 1/20 0.37
KDM4E B2RXH2 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MMP1 P03956 2/20 0.37
MMP2 P08253 2/20 0.37
MMP3 P08254 2/20 0.37
PDE4A P27815 2/20 0.37
PDE4B Q07343 2/20 0.37
PDE4C Q08493 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6404808 0.91 CASR (0.37) KMT2APTGDR2LPAR1MAPTLMNA
SCHEMBL6407165 0.81 CA1 (0.40) ALDH1A1LIMK2MMP1MMP2MMP3
SCHEMBL6401373 0.81 MMP3 (0.40) KMT2AALDH1A1LIMK2MMP1MMP2
SCHEMBL6409458 0.81 NPC1 (0.42) KMT2ALMNAHPGDSMN1; SMN2
SCHEMBL6403038 0.78 CACNA1H (0.41) KMT2AMAPTLMNAALDH1A1CASR
SCHEMBL6403176 0.75 LPAR1 (0.45) KMT2ALPAR1ALDH1A1LIMK2MMP1
SCHEMBL6404802 0.74 CASR (0.38) KMT2APTGDR2LPAR1MAPTALDH1A1
SCHEMBL6408728 0.74 AR (0.41) KMT2AMAPTALDH1A1LIMK2MMP1
SCHEMBL6405206 0.73 CTSS (0.44) LPAR1LIMK2MMP1
SCHEMBL6404812 0.73 NPC1 (0.40) KMT2AMAPTLMNAHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900237-B2 Sulfonamide compounds as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-05-31 US claimed
US-20030158231-A1 Sulfonamide compounds as protease inhibitors Celera Corporation 2003-08-21 US claimed
WO-2003024923-A1 SULFONAMIDE COMPOUNDS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2003-03-27 WO claimed
US-6900237-B2 Sulfonamide compounds as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-05-31 US disclosed
US-20030158231-A1 Sulfonamide compounds as protease inhibitors Celera Corporation 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158231-A1 Sulfonamide compounds as protease inhibitors PRSS1, PRSS3, SPINT2 KMT2A 2789/4885PTGDR2 2472/4885LPAR1 4583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.